Hanall Biopharma Co Ltd
KRX:009420
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of Hanall Biopharma Co Ltd (009420) under the Base Case is KRW per share. Compared with the current market price of 46 700 KRW, the stock appears .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 5 years, and what happened after valuations like today’s.
Create a free account · No card needed
Fundamental Analysis
What Hanall Biopharma Does
HanAll Biopharma Co Ltd is a South Korean drug developer that focuses on antibody-based medicines. It researches, develops, and commercializes biologic drugs for serious diseases, especially immune and inflammatory conditions and other specialist treatment areas. The company’s work starts in the lab and moves through clinical development, regulatory approval, and eventually product sales or licensing deals.
- Headquarters
- Korea KR
- IPO date
- Dec 18, 1989
Revenue & Expenses Breakdown
Hanall Biopharma Co Ltd
Earnings Waterfall
Hanall Biopharma Co Ltd
What is the Intrinsic Value of one Hanall Biopharma Co Ltd stock?
The intrinsic value for Hanall Biopharma Co Ltd (009420) under the Base Case is KRW.
Is Hanall Biopharma Co Ltd stock undervalued or overvalued?
Compared with the current market price of 46 700 KRW, the stock appears .